This low value could be explained by the faint FDG uptake in luminal breast cancer [34] and a lower decrease of FDG tumor uptake under chemotherapy in comparison to more aggressive breast cancer subtypes such as triple negative or HER2-positive BC [10]. This evidence concerns the gene ERBB2 and breast cancer.